Results 11 to 20 of about 70,621 (279)

Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study [PDF]

Oncology and Therapy
Introduction This study evaluated the pharmacokinetic (PK) equivalence between BP02 (a proposed trastuzumab biosimilar) and the reference trastuzumab approved in the EU (EU-trastuzumab) and the US (US-trastuzumab).
Christian Schwabe, Chris Wynne, Dayaker Reddy Dyapa, Arpitkumar Prajapati, Disha Dadke   +4 more
doaj   +2 more sources

Preclinical characterization of 3p-C-DEPA-NCS and 3p-C-DEPA-TFP-PEG4 as potential Actinium-225 bifunctional chelators using DOTA-NCS and macropa-NCS as benchmarks [PDF]

EJNMMI Radiopharmacy and Chemistry
Background Actinium-225 (225Ac) based targeted alpha therapies (TAT) have emerged as a promising strategy for the treatment of several cancer types due to its favourable decay properties, including high linear energy transfer and short particle range ...
Jessica Pougoue Ketchemen, Stephen Ahenkorah, Emmanuel Nwangele, Siphelele Siphesihle Pearl Malaza, Maarten Ooms, Thomas Cardinaels, Simon Leekens, Frederik Cleeren, Humphrey Fonge   +8 more
doaj   +2 more sources

Trastuzumab Deruxtecan-Induced Pneumonitis: Case Series. [PDF]

Clin Case Rep
Three women with HER2‐positive metastatic breast cancer developed pneumonitis or interstitial lung disease after 2–9 cycles of trastuzumab deruxtecan. Presentations ranged from mild cough to CT‐confirmed ILD, often requiring corticosteroids and treatment interruption or discontinuation.
Alhuthali A, Alqurashi B, Banoun Y, Almuylibi Z, Sait H, Al-Sobhi B, Alnuhait M.   +6 more
europepmc   +2 more sources

Development of a High-Throughput LC-MS/MS Method for Simultaneous Quantification of Four Therapeutic Monoclonal Antibodies in Human Serum: Application in Clinical Therapeutic Drug Monitoring. [PDF]

Biomed Chromatogr
ABSTRACT Monoclonal antibody (mAb) therapies have revolutionized cancer treatment, significantly improving patient outcomes. However, the pharmacokinetics (PK) and pharmacodynamics (PD) of mAbs exhibit considerable variability due to nonlinear kinetics and individual differences, highlighting the need for therapeutic drug monitoring (TDM).
Yao Y, Huang GY, Wu TT, Tan TF, Hu FM, Huang C, Gao S, Guo AP, Wang JP.   +8 more
europepmc   +2 more sources

Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study

Breast, 2022
Purpose: To gauge the effects of treatment practices on prognosis for older patients with HER2-positive early breast cancer, particularly to determine whether adjuvant trastuzumab alone can offer benefit over no adjuvant therapy.
Masataka Sawaki, Naruto Taira, Yukari Uemura, Tsuyoshi Saito, Shinichi Baba, Kokoro Kobayashi, Hiroaki Kawashima, Michiko Tsuneizumi, Noriko Sagawa, Hiroko Bando, Masato Takahashi, Miki Yamaguchi, Tsutomu Takashima, Takahiro Nakayama, Masahiro Kashiwaba, Toshiro Mizuno, Yutaka Yamamoto, Hiroji Iwata, Tatsuya Toyama, Koichiro Tsugawa, Takuya Kawahara, Hirofumi Mukai   +21 more
doaj   +1 more source

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

Breast, 2021
Background: Trastuzumab-dkst is a biosimilar of trastuzumab. The phase 3 HERITAGE trial demonstrated equivalent overall response rate (ORR) with trastuzumab-dkst or originator trastuzumab at 24 weeks in patients with HER2-positive metastatic breast ...
Hope S. Rugo, Eduardo J. Pennella, Unmesh Gopalakrishnan, Miguel Hernandez-Bronchud, Jay Herson, Hans Friedrich Koch, Subramanian Loganathan, Sarika Deodhar, Ashwani Marwah, Alexey Manikhas, Igor Bondarenko, Joseph D. Parra, Maria Luisa T. Abesamis-Tiambeng, Charuwan Akewanlop, Ihor Vynnychenko, Virote Sriuranpong, Sirshendu Roy, Eduardo Patricio Yanez Ruiz, Abhijit Barve, Cornelius F. Waller   +19 more
doaj   +1 more source

Incidence of central nervous system metastases in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with trastuzumab: A meta-analysis

Clinics, 2021
This study aimed to estimate the incidence of central nervous system (CNS) metastases in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) treated with trastuzumab.
Xue Bai, Xue Lin, Jin Song, Jia-han Chang, Li-li Han, Cibo Fan   +5 more
doaj   +1 more source

Synthesized Anti-HER2 Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity [PDF]

Iranian Journal of Immunology, 2023
Background: Trastuzumab is a humanized monoclonal antibody that targets site-specifically human epidermal growth factor-2 receptor (HER2) cell surface antigen overexpressed in approximately 20% of human breast carcinomas. Despite its positive therapeutic
Soodabeh Shafiee, Roya Mirzaei, Malihe Salehi, Neda Jalili, Amir Taheri, Leila Farahmand   +5 more
doaj   +1 more source

Trastuzumab [PDF]

The Oncologist, 2011
Abstract Trastuzumab is standard of care in the treatment of human epidermal growth factor receptor (HER)-2+ early and advanced breast cancer. Recently, it has been approved for the treatment of HER-2+ advanced gastric cancer. Trastuzumab is an IgG1 humanized monoclonal antibody administered by intravenous infusion on a weekly or three ...
Boekhout, A.H., Beijnen, J.H., Schellens, J.H.M.   +2 more
openaire   +3 more sources

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer

Technology in Cancer Research & Treatment, 2023
Introduction: This study aimed to compare the efficacy and safety of docetaxel + trastuzumab + pertuzumab and docetaxel + carboplatin + trastuzumab + pertuzumab for treating HER2-positive breast cancer.
Binwei Lin MM, Jinjia Fan MM, Fang Liu MD, Yixue Wen MM, Jie Li MD, Feng Gao MD, Yu Zhang MD, Gang Feng MM, Xiaobo Du MD, Wenzhi Chen MD   +9 more
doaj   +1 more source